EMA · Submission planning advice
EMA publishes year-end 2026 advice for type I variation submissions
Official source date: · Source checked
EMA advises submission by 20 November for specified type IA submissions seeking a 2026 outcome, and by 30 November for type IB submissions seeking a 2026 procedure start.
Who should review this?
Marketing authorisation holders, regulatory operations and pharmaceutical change-control teams.
What it means for pharmaceutical teams
The dates concern year-end processing of the specified type I variation categories. EMA warns that workload can affect timelines and advises earlier submission of type IB procedures where possible.
Practical review checklist
PharmaEdges reading prompts for your own applicability review:
- Identify the variation category and grouping before choosing a submission date.
- Review the 20 November and 30 November advice against the desired outcome or procedure start.
- Allow for questions, submission complexity and the year-end closure.
Official source and verification
Read the EMA source (opens in a new tab)
This article summarises the linked official material. The context and checklist are PharmaEdges explanatory commentary, not additional regulatory requirements. The source publication date is separate from this article’s publication date.
For a correction, contact PharmaEdges with the article URL and supporting source. Read our news publishing policy.
Related regulatory news
- EMA announces permanent clinical-trial application advice from January 2027
- EMA reports on international API inspection cooperation
- India proposes CCTV surveillance at drug sales premises
- India proposes extending prior intimation for certain BA/BE studies